In this ‘Patti’s People’ episode, Patti Peeples of the The Peeples Collaborative speaks with Sarah Emond, President and Chief Executive Officer, ICER.
Questions:
00:00: Introduction
00:44: Tell us about your career over the years, and what your focus is now.
03:59: ICER has been a disruptor in the value assessment space. Where do you see it heading over the next five years?
10:02: What is the goal of ICER’s HEMA collaboration with NICE and CDA?
13:00: What do you see as ICER’s biggest strategic blind spot, and how are you addressing it?
16:28: Looking back, what work do you feel made the greatest impact, and what work should have made a difference but didn’t?
20:35: With CMS now negotiating drug prices under the IRA, how is ICER positioning itself?
23:55: What kinds of activities are you invited to participate in that you are not involved in right now, and why?
26:47: You often balance scientific rigor with public trust – how do you strategically prioritize transparency without paralyzing decision-making?
29:58: How is ICER using AI, and assessing its role in value assessment?
31:37: ICER’s review process is grounded in ethics. Have the ethical considerations changed at any point over the past 19 years?
33:14: Rapid Fire Questions
Sarah K Emond, MPP
President and Chief Executive Officer, ICER
With 25 years of experience in the business and policy of health care, Sarah leads the Institute for Clinical and Economic Review, a leading non-profit health policy research organization, as President and Chief Executive Officer. She joined ICER in 2009 as its first Chief Operating Officer and third employee, and has worked to grow the organization’s approach, scope, and impact over the years.
Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company, and several years with a health care communications firm. Sarah began her health care career in clinical research at Beth Israel Deaconess Medical Center in Boston.
A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor’s degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based health care. In her free time, Sarah enjoys skiing and hiking in the White Mountains of New Hampshire.
","author_name":"The Evidence Base"}